Question 16978 — pharmacy and medicines

Summary

Mr. Quentin Bataillon draws the attention of the Minister of Labor, Health and Solidarity to treatment for dry age-related macular degeneration (AMD). Age-related macular degeneration (AMD) is a retinal condition affecting the macular region, beginning around the age of 55 or later and causing visual deficits. AMD could actually affect around 1,500,000 people in France, all stages confused, early forms and late forms included. There are two forms of AMD: dry and wet. In February 2023, a first treatment was approved for atrophic AMD. Indeed, the Apellis laboratory announced that the Food and Drug Administration (FDA) in the United States of America had validated the injection of pegcetacoplan (marketed under the name Syfovre) as the first treatment for the dry form of AMD. Currently, it is only possible to intervene on the wet form of AMD in France. He would therefore like to know the decision of the European Medicines Agency on the application for marketing authorization for pegcetacoplan to treat dry AMD.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.